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Liquid biopsy mutation panel for non-small cell lung cancer:
analytical validation and clinical concordance
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John P. Bennett 8, Kim Clark-Langone8, Christer Svedman8, Pascale Tomasini9 and Oncotype SEQ® Study Investigators and Program
Team*
Molecular testing for genomic variants is recommended in advanced non-small cell lung cancer (NSCLC). Standard tissue biopsy is
sometimes infeasible, procedurally risky, or insufficient in tumor tissue quantity. We present the analytical validation and
concordance study of EGFR variants using a new 17-gene liquid biopsy assay (NCT02762877). Of 144 patients enrolled with newly
diagnosed or progressive stage IV nonsquamous NSCLC, 140 (97%) had liquid assay results, and 117 (81%) had both EGFR blood
and tissue results. Alterations were detected in 58% of liquid samples. Overall tissue-liquid concordance for EGFR alterations was
94.0% (95% CI 88.1%, 97.6%) with positive percent agreement of 76.7% (57.7%, 90.1%) and negative percent agreement of 100%
(95.8%, 100%). Concordance for ALK structural variants was 95.7% (90.1%, 98.6%). This assay detected alterations in other
therapeutically relevant genes at a rate similar to tissue analysis. These results demonstrate the analytical and clinical validity of this
17-gene assay.
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INTRODUCTION
Improved understanding of the molecular basis of cancer has
enabled the personalized treatment of patients with agents
targeting cancer-specific gene alterations. For example, in non-
small cell lung cancer (NSCLC), targeted therapies are currently
approved and preferred over cytotoxic chemotherapy for patients
with sensitizing EGFR mutations1–4, ALK and ROS1 gene rearrange-
ments5–8, and BRAF variants9. There are additional alterations in
other genes (ERBB2, RET, and MET) with available targeted
therapies and emerging evidence that are included in treatment
guidelines10, including NTRK fusions11. The approval of osimertinib
for patients with emergence of EGFR T790M resistance mutations
highlights the growing importance of assessing and targeting
emerging mutations associated with sensitivity or resistance12.
Assessment of patient tumor genomic alteration status, at
diagnosis and throughout the course of metastatic disease, is
now necessary for optimal therapy.
Even though mutation assessment for EGFR, ALK, and ROS1 has
been standard of care for several years, testing of patients with
advanced disease is suboptimal; reported proportions of patients
without EGFR testing surpass 25% in some countries13,14. In
addition, only a low proportion of patients have mutation test
results available at their first oncology consultation, resulting in
delayed initiation of therapy or initiation of chemotherapy before
diagnostic test results are available13. The causes of suboptimal
mutation assessment are multifactorial, including patient comor-
bidities, complications of lung biopsy such as bleeding, pneu-
mothorax, and infection, and frequently inadequate sampling
leading to costly rebiopsy in about a third of patients15,16.
Furthermore, increasing understanding of tumor heterogeneity
calls into question the representativeness of a biopsy of a single
metastatic site17,18. Thus, alternative, less invasive methods to
assess the genomic alterations of tumors are warranted.
Circulating cell-free DNA (cfDNA) from blood can be used to
detect tumor-specific genomic alterations in the metastatic setting
in various tumor types, and current sequencing technologies allow
for rapid identification of a large number of genomic alterations
from a modest volume of blood19,20. In addition to reducing
discomfort for the patient, assessing genomic alterations in blood
versus tumor tissue may more accurately reflect the mutational
landscape of metastatic lesions at different sites and the molecular
heterogeneity among various tumor sites and regions. Recent data
also indicate that liquid biopsy may be useful for monitoring the
development of alterations associated with acquired resistance, a
potential that carries implications for treatment decisions21,22.
The reported concordance of assessing genomic alterations in
blood versus in tumor tissue varies widely due to multiple factors,
such as the methods used—including analytical platform, varying
tumor burden (lower sensitivity in patients with lower tumor
burden and earlier stages of disease), and genomic coverage of
the regions of interest. It is therefore of clinical importance to
characterize the analytical assay performance in the intended use
population by assessing the concordance of key actionable
genomic alterations detected in plasma with those found in
tissue (biopsy/cytology/excision), the current standard of care. The
ideal plasma ctDNA mutation panel assay would be prospectively
validated in the intended use population and provide clinically
actionable results for all genomic mutations that are associated
with benefit from targeted therapies (that are FDA-approved, in
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ASCO, CAP, NCCN guidelines, or in late-stage clinical development
with evidence of efficacy and safety).
Here we report the analytical validation of a 17-gene next-
generation sequencing (NGS) liquid biopsy panel that assesses
genomic alterations in plasma, including validated alterations that,
when present in the tumor, may portend benefit from targeted
agent treatment approved by regulatory authorities. The panel
also assesses select genes that are targets of therapies in late-
stage clinical trials and genomic alterations that may be relevant
for treatment selection but are supported by preliminary or
preclinical evidence only.
We conducted a prospective study assessing EGFR variant
concordance between liquid and tissue biopsy in patients with
nonsquamous NSCLC for whom the clinical utility of a liquid
biopsy-based mutation assessment is high. Many such patients
may have tumors that are difficult to biopsy or that yield poor-
quality biopsies but for whom knowing the status of genomic
alterations is necessary to select optimal therapy. We present here
the interim analysis of the concordance study.
RESULTS
Analytical validation
Detection thresholds were set to ensure >99% per-sample
specificity. The lowest target amount for 95% detection rate (i.e.,
limit of detection or LOD95) was determined for each variant type
and were as follows: insertions/deletions (indels), 0.1% allelic
fraction (AF); single-nucleotide variants (SNVs), 0.37% AF; struc-
tural variants (SVs), 0.44% AF; and copy number variants (CNVs),
≥3 copies. Using a combination of reference standards and
samples shown to harbor a mutation by digital droplet
polymerase chain reaction, the positive percent agreement (PPA)
and technical positive predictive value were both 98.9%. In the
repeatability and reproducibility study, all expected variants were
observed, indicative of 100% PPA and reproducibility. The detailed
results on specificity, sensitivity, accuracy, repeatability and
reproducibility, interfering substances, stability, contamination,
and cross talk from the analytical validation are provided in the
Supplementary Tables 1–12 and Supplementary Notes.
Clinical concordance study
The clinical concordance study enrolled 157 patients from 16 sites
between April 2016 and October 2017. Thirteen patients were
excluded due to failure to satisfy eligibility criteria, including
absence of tissue samples, presence of treatment between tissue
and liquid biopsies, withdrawal of consent, or death prior to blood
draw. The vast majority (140/144) of protocol-eligible patients had
evaluable liquid assay results including 121 cohort A patients
(those with newly diagnosed metastatic disease or progressive
disease on any-line non-EGFR-targeted therapy) and 19 cohort B
patients (those with progressive disease on EGFR-targeted
therapy). Four samples were excluded due to blood preprocessing
issues; there were no laboratory failures. In cohort A, 117 patients
had concurrent EGFR tissue results, with a median of 27 days
(interquartile range 14–35) between tissue and blood collection.
Patient demographics and clinical characteristics are presented
in Table 1. In cohort A, which was used for the primary analysis of
tissue/liquid concordance for EGFR mutational status, 61% of
patients were white and 50% female. The average age was 66
years (range 42–94 years). A large majority of these patients (93%)
were newly diagnosed with stage IV NSCLC. Nearly half (48%) of
patients had two or more organs with metastases and about
three-fourths (74%) had two or more metastatic lesions in all
organs.
Alterations reported by the liquid biopsy assay are presented in
Figs. 1 and 2. Overall, the liquid biopsy assay identified 120
alterations across 13 genes in 81/140 (58%) patients, including
EGFR (29%), KRAS (16%), MET (7%), ALK (4%), ERBB2 (4%), RET (2%),
BRAF (1%), and ROS1 (<1%). More than half (54%) of alterations
were SNVs, 23% indels, 14% CNVs, and 8% SVs. Most (51/81)
patients had only one alteration reported.
In cohort A, the liquid biopsy assay identified 90 genomic
alterations in 66 (55%) patients. Among the 90 alterations were 34
EGFR variants, which included 13 exon 19 deletions and 14 SNVs.
Ten of the EGFR SNVs are included in the primary analysis (L858R
[n= 6], G719A [n= 2], L861Q [n= 2]). Four other EGFR SNVs were
found, including one T790M. In 19 cohort B patients (progressing
on erlotinib, gefitinib, or afatinib), the assay detected 30 genomic
alterations: 13 EGFR SNVs (T790M [n= 6], L858R [n= 3], G719A
[n= 1], L861Q [n= 1], S768I [n= 1], V769L [n= 1]), five EGFR
CNVs, eight EGFR deletions, one EGFR insertion, and one SNV each
in ERBB2, KRAS, and PIK3CA. The prevalence of EGFR T790M in
Table 1. Patient demographics and clinical characteristics for the
clinical concordance study.
Cohort A
(n= 121)
Cohort B
(n= 19)
Age, years
Median (range) 66 (42–94) 67 (45–85)
Female 61 (50.4%) 10 (52.6%)
Ethnicity
Not Hispanic or Latino 91 (88.3%) 12 (92.3%)
Hispanic or Latino 3 (2.9%) 1 (7.7%)
Not reported 9 (8.7%) 0 (0.0%)
Race
White 74 (61.2%) 9 (47.4%)
Asian 14 (11.6%) 4 (21.1%)
Black or African American 8 (6.6%) 0 (0.0%)
Not reported 25 (20.7%) 6 (31.6%)
Progression status at enrollment
Newly diagnosed with stage IV
disease
113 (93.4%) 0 (0.0%)
Progressing on treatment 8 (6.6%) 19 (100%)
Number of months from diagnosis to progression
Median (range) 18 (4–53) 15 (2–79)
Nonsquamous NSCLC subtype
Adenocarcinoma 117 (96.7%) 19 (100%)
Large cell carcinoma 3 (2.5%) 0 (0.0%)
Other 1 (0.8%) 0 (0.0%)
Number of organs with metastases
1 57 (47.1%) 6 (31.6%)
2 or more 58 (47.9%) 12 (63.2%)
LN metastases only 6 (5.0%) 1 (5.3%)
Number of total metastatic lesions in all organs
1 32 (26.4%) 4 (21.1%)
2 or more 89 (73.6%) 15 (78.9%)
Country
France 18 (14.9%) 6 (31.6%)
Ireland 0 (0.0%) 1 (5.3%)
Japan 5 (4.1%) 3 (15.8%)
Spain 27 (22.3%) 7 (36.8%)
United Kingdom 7 (5.8%) 0 (0.0%)
United States of America 64 (52.9%) 2 (10.5%)
LN lymph node, NSCLC non-small cell lung cancer.
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patients progressing on EGFR-targeted therapy was 32% (95% CI:
13–57%).
In the primary concordance analysis of 117 cohort A patients
with evaluable tissue and liquid results, there was substantial
variation in the tissue tests used (Supplementary Table 13) and the
methodology: polymerase chain reaction (52.1%), NGS (32.5%),
Sanger (14.5%), and restriction fragment length polymorphism
(0.9%). Of 157 enrolled patients, the central Clinical Laboratory
Improvement Amendments (CLIA) laboratory test (Foundatio-
nOne®, Foundation Medicine, Cambridge, MA) was ordered in 33
patients. Eleven (33%) of these tests failed due to insufficient
tumor, DNA yield, or tumor purity metrics. In some patients, a
small amount of residual material was available after local tissue
assessment, increasing the risk of failure due to biopsy volume.
Concordance results for alterations in EGFR and ALK are shown
in Table 2. Thirty patients had the prespecified EGFR mutations
(exon 19 deletions, L858R, L861Q, G719X, and S768I) in tissue and
23 had these mutations in plasma. All patients with EGFR
alterations detected in plasma had the same alterations detected
in tissue, resulting in a PPA of 76.7% (95% CI: 57.7–90.1%) and a
negative percent agreement (NPA) of 100% (95.8–100%). The
overall concordance was 94.0% (88.1–97.6%). Patients with EGFR
alterations reported in tissue but not in plasma tended to have
lower tumor burden as indicated by lower DNA yields from blood
and a lower proportion of patients with evidence of disease in two
or more organs (Supplementary Fig. 1).
Ten patients had ALK translocations detected in tissue, five of
whom had ALK alterations detected in liquid, with a resulting PPA
of 50.0% (18.7–81.3%), NPA of 100.0% (96.5–100.0%), and overall
percent agreement (OPA) of 95.7% (90.1–98.6%). In one patient
with an alteration detected in tissue only, the liquid biopsy signal
for ALK translocation was just below the threshold for calling the
variant. The details of concordance for each gene in the panel are
presented in Supplementary Table 14. The number of assessments
in tumor tissue for some of the genes was limited.
Among patients with key EGFR alterations (listed in Table 2) in
both tissue and liquid (n= 23) the best response (by imaging and/
or clinical assessment) in patients treated with targeted therapy
was available in 21 patients. According to both imaging and
clinical assessment, there was partial response in 11 patients (52%)
and stable disease in 10 (48%). In patients with EGFR alterations
detected in tissue only, the response rate was captured in six of
seven patients. Best response (by imaging and/or clinical
assessment) was partial response in three patients (50%) and
stable disease in three patients (50%).
An ad hoc analysis was performed to examine the association of
response rate with AF. In patients with AF below 1%, 2/8 (25%)
had partial responses and 6/8 (75%) had stable disease. In patients
with an AF of 1% or above, 9/13 (69%) had partial responses and
4/13 (31%) had stable disease.
Best response to first therapy after liquid biopsy was available in
five of five patients with ALK alterations detected in both tissue
and liquid. All patients received ALK-targeted therapy. Two
patients (40%) had complete responses and two patients had
partial responses (40%) by imaging. One patient (20%) had
progressive disease by clinical assessment. Among the five
patients with ALK alterations detected in tissue only, four had
best response data available: one had a complete response, one
had stable disease, and two had progressive disease.
DISCUSSION
There are many potential uses of liquid biopsy testing in oncology,
from screening of early-stage disease to monitoring of treatment
effect. Presently, there is relatively little evidence supporting the
Fig. 1 Number of alterations by gene reported in the liquid
biopsy assay for 140 patients in cohorts A and B. CNV copy
number variant, SNV single-nucleotide variant, SV structural variant.
Fig. 2 Alterations detected in liquid biopsy in cohorts A and B, by gene and patient (n= 81 patients with at least one alteration
detected). Each row represents a gene and each column represents an individual patient. CNV copy number variant, SNV single-nucleotide
variant, SV structural variant.
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utility of such testing for most of these purposes, except for
patients with advanced or metastatic disease who are candidates
for systemic targeted therapy but in whom tissue testing cannot
be performed successfully23. Such patients may have insufficient
diagnostic tissue for testing or may be difficult to biopsy because
of tumor location, comorbidities, bleeding disorders, or a strong
personal preference. Even in these patients, only limited data from
prospective studies exist to support use of tests assessing
actionable genomic alterations across multiple genes, despite a
high unmet need. Data also support liquid biopsy assessment in
patients progressing on targeted therapy where there are
identified acquired mutations associated with resistance and
sensitivity to other drugs and where the patient is challenging to
biopsy21,22.
In previously reported prospective clinical concordance studies,
the sensitivity and specificity for detecting EGFR mutations in
liquid versus tissue was similar to that reported for the approved
Cobas EGFR test24–26. The analytical validation of the liquid biopsy
assay described herein demonstrated high sensitivity, specificity,
and reproducibility for detecting SNVs, indels, SVs, and CNVs.
Importantly, there were no EGFR alterations found in liquid that
were not present in tumor tissue in newly diagnosed patients,
leading to an NPA of 100%. The PPA below 80% supports reflex
tumor tissue testing when a liquid test is negative, similar to the
Cobas EGFR test. The OPA for all SNVs, indels, and CNVs in the
panel was comparable with that for EGFR (SNV 89.7%
[82.8–94.6%], indels 95.7% [90.3–98.6%], CNVs 90.3%
[74.2–98.0%]). The OPA for translocations was also similar to
EGFR, while the PPA based on 14 positive patients was somewhat
lower (50% [23.0–77.0%]). Gene rearrangements can be more
challenging to identify than SNVs or small indels when using
hybrid capture versus amplicon-based enrichment methodologies.
It is thus possible that the true concordance between cfDNA and
tissue indeed may be lower for gene rearrangements than for
SNVs when using hybrid capture technologies.
Overall, the data across many studies using a variety of modern
methods demonstrate sensitivities for EGFR alterations assessed in
liquid biopsy versus tumor tissue to be in the 70–85% range in
patients with metastatic disease24–36. The consistency of our
results with published data suggests that this sensitivity limit is
driven in part by biological constraints, perhaps disparity in overall
tumor burden or differences in DNA shedding from tumor cells in
various tissue locations. Our planned analysis by tumor burden
revealed that failure to detect alterations in liquid was associated
with lower tumor burden, as indicated by lower DNA yields from
blood and evidence of disease in fewer than two organs. These
findings are consistent with the literature33. It is important to
recognize that the theoretical biological limit of sensitivity to
detect tumor mutations is a function of both tumor mutant AF
and the total amount of DNA. While some assays, in principle, may
have an LOD95 of 0.001% using contrived samples containing
more genome equivalents than present in a typical patient
sample, it is unlikely that this can be consistently achieved in
clinical samples. Thus, samples containing a representative
number of genome equivalents are recommended when
establishing LOD95. The ability to make correct variant calls at
very low AF is important, as recent evidence shows that patients
with very low variant AFs may have excellent responses to
targeted therapy37. In our study, although the number of patients
with an AF below 1% was small, a high proportion of these had
partial response or stable disease consistent with benefit from
EGFR-directed therapy.
The results from the cohort of patients progressing on erlotinib,
gefitinib, or afatinib demonstrate that the assay can be used to
detect alterations associated with resistance/sensitivity in patients
progressing on therapy. The reported rate of EGFR T790M of 32%
is on the lower end of that reported in the literature based on
tumor tissue testing38–40, possibly reflecting the small sample size
or the high proportion of Japanese patients in this cohort (the
T790M mutation rate in Japanese patients may be lower than in
Caucasians)41. In addition, the cohort is somewhat enriched in
EGFR-mutant patients due to the participation of a Japanese site,
as well as sites that are referral centers for EGFR-mutant patients.
The patient population is thus not completely representative of an
all-comer patient population in either Caucasians or East Asians,
but the enrichment of EGFR-mutant patients was important in
order to make study accrual feasible.
The FDA recently approved a broad tumor tissue mutation
panel42, which will likely increase the use of broad mutational
profiling. However, the sample requirements for broad panel
testing can lead to high test failure rates in small samples: over
28% for endoscopic biopsies and 51% for fine-needle aspirates43.
This is an especially important issue in lung cancer, where there
are many actionable alterations yet the NGS test failure rate is over
26%43. This could create an increased need for rebiopsy, a possible
shift toward larger biopsies with higher risks of adverse events, or
an alternative assessment by liquid biopsy. In our study, the
clinical outcome captured in patients mutation-positive by liquid
biopsy is consistent with what has been reported for patients
mutation-positive by tumor tissue biopsy. Given 100% NPA and a
PPA of less than 80% for the liquid biopsy assay, a negative liquid
biopsy should trigger a reflex tumor tissue biopsy if feasible. It
should be emphasized that tissue biopsy still has the advantage of
providing diagnostic/histological information and suitable mate-
rial for the assessment of PD1/PDL1 status and other histologic
assessments, such as tumor-infiltrating lymphocytes. Given
current guidelines that strongly recommend first-line treatment
with targeted agents rather than immunochemotherapy for
patients with sensitizing alterations in EGFR, ALK, ROS1, and
BRAF10, an initial liquid biopsy assessment may be medically
appropriate in many patients and could potentially reduce delays
in initiation of treatment that cause anxiety in patients44. Patient
preference regarding liquid biopsy versus tissue biopsy is not well
documented but is a field where research is warranted, as it seems
likely that many patients would strongly prefer a less invasive and
risky procedure.
There are limitations to the conclusions that can be drawn from
this concordance study. While a comparison of liquid biopsy to
tumor tissue biopsy results is needed for assay validation, the
clinical advantages of liquid biopsy may be most obvious for
Table 2. Positive percent agreement (PPA), negative percent agreement (NPA), and overall percent agreement (OPA) with 95% confidence intervals
for key EGFR and ALK alterations in cohort A.
Alteration n PPA NPA OPA
EGFR
Exon 19 deletions, L858R, L861Q, G719X, or S768I 117 76.7% (57.7%, 90.1%) 100.0% (95.8%, 100%) 94.0% (88.1%, 97.6%)
ALK
Structural variants 115 50.0% (18.7%, 81.3%) 100.0% (96.5%, 100.0%) 95.7% (90.1%, 98.6%)
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patients who do not have tissue results, either because of tissue
assay failure or because the tumors are challenging to biopsy.
Thus, the study population may not be fully representative of a
primary target population for clinical use. The large majority of
patients in this study had de novo metastatic disease, and it is
possible that relapsing patients have a differential expression of
liquid versus tissue genomic alterations. Location of the primary
tumor and metastatic lesions is likely the most common reason
making biopsy difficult and risky. As data in the literature and our
results indicate, a lower tumor burden may be associated with a
lower sensitivity. In addition, the study permitted local assessment
of mutation status in tumor tissue and many different methods
were used. Central assessment using an NGS panel was offered for
all patients, but only ~30% of patients underwent testing with the
central NGS panel. The reasons for this fairly low rate of central
testing may include a preference for faster local results or the lack
of sufficient residual material after local testing. The heterogeneity
of tests and methods used for tumor tissue assessment can be
seen as a strength of this study, however, as it reflects current
clinical practice. Importantly, that the NPA was 100% and that the
concordance was similar when compared with either central NGS
tests or local tests indicate that the results were not negatively
impacted.
In conclusion, the 17-gene liquid biopsy panel is analytically
validated with consistent performance across SNVs, indels,
translocations, and CNVs. The concordance with tumor tissue
biopsy for clinically relevant alterations in EGFR is comparable with
that of the approved liquid Cobas EGFR test. In addition, the 17-
gene panel can detect alterations in other genes relevant for
treatment decisions in NSCLC. Liquid biopsy assessment may be
clinically helpful in the substantial proportion of patients for
whom obtaining a tissue biopsy is challenging, there is a strong
patient preference, or tissue biopsy or analysis has failed.
METHODS
The 17-gene liquid biopsy assay was performed in a single CLIA-certified
laboratory at Genomic Health, Inc. (Redwood City, CA). Plasma was
obtained from whole blood (2 × 10mL tubes, Cell-Free DNA BCT, Streck)
using the standard double spin method; blood was spun for 10min at
1500 g ± 150 g, plasma isolated and re-spun at 3000 g ± 150 g for 10 min,
and transferred to a clean tube. Extraction was performed using a
proprietary methodology based on the MagMAX Cell-Free DNA Isolation
Kit (Thermo Fisher Scientific). DNA quantitation was performed using the
Quant-iT™ PicoGreen® dsDNA kit (Thermo Fisher Scientific). To mimic
cfDNA, reference control genomic DNA was sheared using the E220
Focused-Ultrasonicator (Covaris) followed by size selection using AMPure
XP Beads (Agencourt/Beckman Coulter). The resulting DNA was assessed
using the 2100 Bioanalyzer (Agilent) and samples required to be >100 and
<200 bp. Whole genome libraries were prepared by a proprietary
methodology using the KAPA Hyper Prep Kit (Kapa Biosystems/Roche)
and dual-indexed adapters (Integrated DNA Technologies). Resulting pond
libraries were quantified and quality controlled using the 4200 TapeStation
Instrument (Agilent Genomics). Hybrid capture was performed using a
modified SeqCap EZ HyperCap (NimbleGen/Roche) workflow and baits
(Integrated DNA Technologies) designed to cover the 17-gene target
regions. The genes and alterations covered in the panel are detailed in
Table 3. Enriched libraries were quantified using the 4200 TapeStation
Instrument (Agilent Genomics).
Paired-end sequencing was performed on the HiSeq® 2500 (Illumina).
Samples to be sequenced on the same flowcell were pooled together at
7 pM. Clustering was performed using the HiSeq Rapid PE Cluster Kit v2
(Illumina) and performed on the HiSeq® 2500. Samples were sequenced for
101 cycles for both Read 1 and Read 2. PhiX Control (Illumina) was
included on each flowcell and used as a sequencing control. For variant
calling of SNV and copy number variant (CNV), proprietary continuous
metrics based on probabilistic models were employed. Final baseline
parameter values for models were derived using data from an
independent set of 103 cfDNA samples from healthy volunteers. Indels
and SV detection were achieved using proprietary bioinformatic algo-
rithms. In all cases, selection of detection rules and cutoffs was informed by
limit of blank (LOB) for each of the various detection metrics, in order to
control for specificity. A propriety SNP-signature comparison module was
developed to identify potential pre-index cross-contamination or carryover
between samples, validated in the Interfering Substances Study and
applied to all relevant Analytical Validation studies and Clinical Validation.
A detailed technical description of the analytical validation, including
design and statistical analysis, methods for LOB, limit of detection,
interfering substances, and accuracy studies is included in the Supple-
mentary File.
Clinical concordance study
We conducted a global multicenter prospective clinical study
(NCT02762877) to characterize the concordance of key clinically relevant
genomic alterations in DNA extracted from formalin-fixed, paraffin-
embedded tumor tissue (biopsy/excision/cytology) and in cfDNA from
liquid biopsy (blood), and the frequencies of genomic alterations identified
in liquid biopsy (listed in Table 3) in patients with stage IV nonsquamous
NSCLC. Patients seeking treatment at 16 oncology centers in the United
States of America, Europe, and Japan who were identified to meet
eligibility criteria were enrolled. The study enrolled two cohorts: cohort A,
patients who were either newly diagnosed with metastatic disease or
progressive disease on non-EGFR-targeted therapy (any line); and cohort B,
patients with progressive disease on EGFR-targeted therapy (erlotinib,
gefitinib, afatinib). Full inclusion and exclusion criteria are in Supplemen-
tary Table 15. All samples were collected with institutional review board
approval (Asentral IRB) and written informed patient consent. Concordance
analysis focused on cohort A. Tissue biopsy and blood collection were less
than 8 weeks apart with no new systemic antitumoral treatment given in
the interval between the tissue biopsy and blood collection (local therapy,
such as radiation, was permitted). Tissue analysis by a central CLIA
laboratory (Foundation Medicine, Inc.) was offered but not required. The
results of the central laboratory assessment were used in the concordance
Table 3. Genes/alterations included in the 17-gene liquid
biopsy panel.
Gene Variant type(s) reported
ALK Targeted and de novo SNVs, targeted and de novo SVs
AR Targeted and de novo SNVs
BRAF Targeted and de novo SNVs, targeted and de novo indels
BRCA1 Targeted and de novo SNVs, targeted and de novo indels
BRCA2 Targeted and de novo SNVs, targeted and de novo indels
EGFR Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
ERBB2 Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
ESR1 Targeted and de novo SNVs, CNV gains
KIT Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
KRAS Targeted and de novo SNVs, targeted and de novo indels
MET Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
NRAS Targeted and de novo SNVs
PDGFRA Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
PIK3CA Targeted and de novo SNVs, CNV gains, targeted and de
novo indels
PTEN Targeted and de novo indels
RET Targeted and de novo SNVs, targeted and de novo indels,
targeted and de novo SVs
ROS1 Targeted and de novo SNVs, targeted and de novo SVs
The panel includes detection of single-nucleotide variants (SNVs), copy
number variant (CNV) gain or loss, targeted insertions/deletions (indels),
and targeted structural variants (SVs).
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analysis. If no central laboratory result was available, the results from the
local assessment of genomic alteration status in tissue were used. In
addition, detection of EGFR T790M alterations in plasma was characterized
in cohort B patients where tissue sample collection was not required.
Patients were followed to collect treatment given after liquid biopsy, best
response to this treatment (complete response, partial response, stable
disease, or progressive disease), and date of clinical or radiological
progression for up to 12 months after liquid biopsy. Presence of any of the
prespecified clinically actionable EGFR alterations (exon 19 deletions,
L858R, L861Q, G719X, and S768I) was considered as EGFR-positive for the
primary analysis. PPA, NPA, and OPA were calculated45. Two-sided 95%
Clopper–Pearson confidence intervals were reported. The interim analysis
was prespecified to occur after enrollment of at least 30 patients with EGFR
alterations. Individuals involved in laboratory analysis of liquid samples
were blinded to clinical data and tissue biopsy results. Data were analyzed
using SAS software, version 9.4, of the SAS System for Windows (Copyright
2018 SAS Institute Inc. SAS and all other SAS Institute Inc. product or
service names are registered trademarks or trademarks of SAS Institute Inc.,
Cary, NC, USA).
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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